{"id":"NCT02280473","sponsor":"Allergan","briefTitle":"A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-13","primaryCompletion":"2015-03-16","completion":"2015-03-16","firstPosted":"2014-10-31","resultsPosted":"2017-06-07","lastUpdate":"2019-04-16"},"enrollment":188,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndromes"],"interventions":[{"type":"DRUG","name":"Refresh Optive® Gel Drops","otherNames":[]},{"type":"DRUG","name":"REFRESH LIQUIGEL®","otherNames":[]}],"arms":[{"label":"Refresh Optive® Gel Drops","type":"EXPERIMENTAL"},{"label":"REFRESH LIQUIGEL®","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.","primaryOutcome":{"measure":"Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score","timeFrame":"Baseline, Day 30","effectByArm":[{"arm":"Refresh Optive® Gel Drops","deltaMin":42.44,"sd":11.708},{"arm":"REFRESH LIQUIGEL®","deltaMin":40.43,"sd":11.232}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["30573298"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":94},"commonTop":["Vision blurred"]}}